PLoS ONE (Jan 2018)

The interaction between N-terminal pro-brain natriuretic peptide and fluid status in adverse clinical outcomes of late stages of chronic kidney disease.

  • Yi-Chun Tsai,
  • Hui-Ju Tsai,
  • Chee-Siong Lee,
  • Yi-Wen Chiu,
  • Hung-Tien Kuo,
  • Su-Chu Lee,
  • Tzu-Hui Chen,
  • Mei-Chuan Kuo

DOI
https://doi.org/10.1371/journal.pone.0202733
Journal volume & issue
Vol. 13, no. 8
p. e0202733

Abstract

Read online

INTRODUCTION:Fluid overload is one of the major characteristics and complications in patients with chronic kidney disease (CKD). N-terminal pro-brain natriuretic peptide (NT-proBNP) is related to fluid status and fluid distribution. The aim of this study is to investigate the interaction between NT-proBNP and fluid status in adverse clinical outcomes of late stages of CKD. METHODS:We enrolled 239 patients with CKD stages 4-5 from January 2011 to December 2011 and followed up until June 2017. Fluid status was presented as hydration status (HS) value measured by body composition monitor, while HS>7% was defined as fluid overload. Clinical outcomes included renal outcomes (commencing dialysis and estimated glomerular filtration rate decline>3 ml/min/1.73 m2/year), all-cause mortality and major adverse cardiovascular events (MACEs). RESULTS:During a mean follow-up of 3.3±2.0 years, 129(54.7%) patients commenced dialysis, 88(37.3%) patients presented rapid renal function decline, and 48(20.3%) had MACEs or died. All patients were stratified by HS of 7% and the median of plasma NT-proBNP. The adjusted risks for commencing dialysis was significantly higher in patients with high plasma NT-proBNP and HS>7% compared to those with low plasma NT-proBNP and HS≦7%. There was a significant interaction between plasma NT-proBNP and HS in commencing dialysis (P-interaction = 0.047). Besides, patients with high plasma NT-proBNP and HS>7% had greater risks for MACEs or all-cause mortality than others with either high plasma NT-proBNP or HS>7%. CONCLUSION:NT-proBNP and fluid overload might have a synergistic association of adverse clinical outcomes in patients with late stages of CKD.